Suraksha Diagnostics

Kolkata, India Founded: 2005 • Age: 21 yrs Listed
Pathology, molecular diagnostics, and imaging services are provided.
Request Access
Report Incorrect Data
Page last updated

About Suraksha Diagnostics

Suraksha Diagnostics is a publicly listed company based in Kolkata (India) founded in 2005. Pathology, molecular diagnostics, and imaging services are provided. Suraksha Diagnostics has raised $49 million across 2 funding rounds from investors including Orbimed and Lighthouse Funds. The company has 1,300 employees. Suraksha Diagnostics was last valued at $35.76 million in February 2013. Its chief executive, as recorded, is Raman Kejriwal. Its website surakshanet.com draws about 101 thousand monthly visits. Its Indian entity Suraksha Diagnostic Limited reported revenue of ₹11.40 Cr. Suraksha Diagnostics offers products and services including MRI Scan, X Ray, Pathology Testing, ECG Test, and Blood Tests. Its focus areas include Clinical Laboratory Chains and Diversified. Its competitors include Thyrocare, Aarthi Scans and Vijaya Diagnostic Centre; 1 of its 3 listed competitors has raised funding.

Company details

Suraksha Diagnostics was founded in 2005 in Kolkata, India, as a provider of diagnostic services in the healthcare sector. A wide range of tests is offered, including radiology, histopathology, molecular biology, cytogenetics, cardiology, gastroenterology, and neurology. Operations are supported by online booking for tests and electronic access to medical reports via the website, serving patients across the region.

  • Headquarters Kolkata, India
  • Employees 1,300
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website surakshanet.com
  • Social LinkedIn X Facebook
  • Legal Name Suraksha Diagnostic Ltd.
Operational Areas
Healthcare → Diagnostics Laboratories
Key Metrics
  • Market Cap
    ₹1,510 Cr

    SURAKSHA · NSE

  • Share Price
    ₹288.95

    -0.34% today

  • Revenue
    ₹310 Cr

    FY 2025-26 · +23.1% YoY

  • EBITDA
    ₹96.17 Cr

    Margin 31.0%

  • Net Profit
    ₹32.37 Cr

    FY 2025-26 · +1.1% YoY

  • P/E (TTM)
    43.4x

    P/B 6.3x

  • ROE
    13.8%

    ROCE 16.6%

  • Debt / Equity
    0.48

    Interest cover 24.4x

  • Total Equity Funding
    $49M (USD)

    in 2 rounds

  • Latest Funding Round
    $40M (USD), Series B

    Dec 2016

  • Investors
    Orbimed

    & 1 more

  • Employee Count
    1,300

Products & Services of Suraksha Diagnostics

Suraksha Diagnostics offers a comprehensive portfolio of products and services, including MRI Scan, X Ray, Pathology Testing, ECG Test, and Blood Tests.

MRI Scan
Imaging

Advanced imaging for detailed internal body diagnostics

X Ray
Imaging

Basic imaging to detect bone and tissue abnormalities

Pathology Testing
Laboratory

Tests for microbiology and histopathology analysis

ECG Test
Cardiology

Heart activity monitoring for diagnostic purposes

Blood Tests
Pathology

Laboratory analysis of blood samples for health checks

Funding Insights of Suraksha Diagnostics

Suraksha Diagnostics has successfully raised a total of $49M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $49M
  • Total Rounds 2
  • Last Round Series B — $40M
  • First Round $9M

    (Feb 2013)

  • Investors Count 2

All 2 funding rounds of Suraksha Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2016$40MSeries B–Orbimed
–
Feb 2013$9MSeries A$35.76MLighthouse
–
Valuation history
DateValuationStage
Feb 2013$35.76M••••••••

Last known valuation $35.76M (Feb 2013). 2 investors in total: 2 institutional.

Investors in Suraksha Diagnostics

Suraksha Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and Lighthouse Funds.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Orbimed
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Lighthouse Funds
Investment funds for Indian startups are managed by Lighthouse.
lhfunds.comMumbai, India
Premium access

Investor details for Suraksha Diagnostics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Suraksha Diagnostic Limited (Suraksha Diagnostics)

Suraksha Diagnostic Limited is the primary company behind Suraksha Diagnostics. The boards of the 6 registered companies of Suraksha Diagnostics currently have 18 directors; the longest-serving is Gautam Ghosh, appointed in 1991. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Gautam Ghosh
DIN 00137133
Director27 Jun 199135 yrs 3 moSuraksha Diagnostic & Eye Centre Private Limited
Tandra Chatterjee
DIN 00471613
Director27 Jun 199135 yrs 3 moSuraksha Diagnostic & Eye Centre Private Limited
Suparna Ghosh
DIN 00137206
Director01 Apr 199333 yrs 6 moSuraksha Diagnostic & Eye Centre Private Limited
Seema Kejriwal
DIN 02635749
Director01 Apr 200917 yrs 6 moSuraksha Diagnostic & Eye Centre Private Limited
Vishal Kejriwal
DIN 01142949
Director01 Apr 200917 yrs 6 moSuraksha Diagnostic & Eye Centre Private Limited
Shalabh Jalan
DIN 01089278
Designated Partner06 Aug 20188 yrs 2 moTerriific Electricals Llp
Raman Kejriwal
DIN 02441014
Designated Partner06 Aug 20188 yrs 2 moTerriific Electricals Llp, Suraksha Diagnostic & Eye Centre Private Limited
Somnath Chatterjee
DIN 00137075
Designated Partner06 Feb 20197 yrs 8 moSuraksha Speciality Llp, Suraksha Salvia Llp, Asian Institute Of Immunology & Rheumatology Llp, Suraksha Diagnostic & Eye Centre Private Limited, Suraksha Diagnostic Limited
Ritu Mittal
DIN 00165886
Designated Partner06 Feb 20197 yrs 8 moSuraksha Speciality Llp, Suraksha Diagnostic Limited
Christopher Rani
DIN 07107480
Designated Partner26 Jul 20197 yrs 2 moSuraksha Salvia Llp
Parthajit Das
DIN 09734003
Designated Partner17 Jul 20233 yrs 3 moAsian Institute Of Immunology & Rheumatology Llp
Ajoyendra Nath Chattopadhyay
DIN 10241409
Designated Partner17 Jul 20233 yrs 3 moAsian Institute Of Immunology & Rheumatology Llp
Uma Kejriwal
DIN 00206097
Director15 May 20242 yrs 5 moSuraksha Diagnostic & Eye Centre Private Limited
Pradip Kumar Dutta
DIN 00654286
Director16 Jul 20242 yrs 3 moSuraksha Diagnostic Limited
Satish Kumar Verma
DIN 00225444
Director16 Jul 20242 yrs 3 moSuraksha Diagnostic Limited
Ishani Ray
DIN 08800793
Director16 Jul 20242 yrs 3 moSuraksha Diagnostic Limited
Siddhartha Roy
DIN 00042757
Director03 Oct 20242 yrsSuraksha Diagnostic Limited
Dharam Chand Dharewa
DIN 05327284
Director03 Oct 20242 yrsSuraksha Diagnostic Limited

People of Suraksha Diagnostics

9 people are tracked at Suraksha Diagnostics (4 in leadership, 5 in team); the tracked headcount is 1,300.

NameRoleGroup
Raman Kejriwal
CEO & DirectorLeadership
Ritu Mittal
Chief Executive OfficerLeadership
Niren Kaul
Head Of OperationsLeadership
Surender Kumar Pandey
Head Of Sales MarketingLeadership
Pallabi Das
Floor ManagerTeam
Sanjeeb Das
Assistant Manager OperationTeam
Meenakshi Gupta
Senior Manager OperationsTeam
Simanta Chatterjee
Area Business ManagerTeam
Sangeeta Chakaborty
Manager Admin OperationsTeam
Premium access

Complete people profiles for Suraksha Diagnostics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Suraksha Diagnostics

Suraksha Diagnostics is a publicly listed company on the NSE with ticker symbol SURAKSHA in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date06 Dec 2024
  • Listed onNSE: SURAKSHA · BSE: 544293
  • Listed entitySuraksha Diagnostic Ltd.
  • Exchange sectorHealth services
  • ISININE877V01027
  • Share price₹316.70 (+0.73% on the day) · 2026-10-14
  • Market capitalisation₹1,634 Cr
  • Price to earnings46.1
  • EPS (diluted, trailing year)₹6.87
  • Dividend yield0.16%
  • Volume (last session)24,776

Financials of Suraksha Diagnostics

Exchange-reported figures of Suraksha Diagnostic Limited, the listed company behind Suraksha Diagnostics (NSE: SURAKSHA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹310 Cr
+23.1% YoY
EBITDA
₹96.17 Cr
+17.4% YoY
Profit After Tax
₹32.37 Cr
+1.1% YoY
Net Worth
₹245 Cr
+15.9% YoY
Total Assets
₹397 Cr
+32.1% YoY
Total Debt
₹130 Cr
+46.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue310252219190223140158
Revenue growth+23.1%+15.3%+15.0%-14.8%+59.4%-11.1%-
EBITDA96.1781.9370.1144.4348.0822.6234.10
EBITDA margin+31.0%+32.5%+32.1%+23.4%+21.5%+16.2%+21.7%
Profit before tax44.5441.4131.466.7533.196.3921.02
Net profit32.3732.0325.677.6824.768.1415.00
Net profit margin+10.4%+12.7%+11.7%+4.0%+11.1%+5.8%+9.5%
EPS (₹)6.186.1134.249.45344.2093.26220.48
Balance sheet
Total assets397300270253169143131
Net worth245211179156150126120
Total debt13088.8990.4896.8819.0216.4311.59
Cash & bank26.3520.1155.0255.042.824.433.92
Net working capital18.9719.2348.0146.220.443.49(7.26)
Cash flow
Cash from operations81.8363.3660.4844.1042.3423.5131.31
Cash from investing(52.17)(39.58)(35.00)(20.79)(43.79)(27.71)(19.79)
Cash from financing(28.69)(24.05)(25.13)(24.33)1.093.21(10.16)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue87.6581.4177.6978.7372.5965.0959.5166.75
Revenue growth (YoY)+20.8%+25.1%+30.6%+18.0%+19.5%---
Other income1.090.790.620.850.910.820.601.31
EBITDA30.4524.3723.1624.1223.7519.1818.2523.19
EBITDA margin+34.7%+29.9%+29.8%+30.6%+32.7%+29.5%+30.7%+34.7%
Depreciation11.2811.2610.5610.149.488.738.838.75
Interest3.723.923.162.782.702.061.982.13
Profit before tax16.549.9810.0612.0512.489.218.0413.62
Tax3.683.822.823.223.302.042.063.48
Net profit12.866.167.248.839.187.175.9810.14
EPS (₹)2.501.211.441.731.801.421.181.94
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue301249219190223140158
Revenue growth+20.7%+14.0%+15.0%-14.9%+59.4%-11.1%-
EBITDA95.5483.2671.1945.4848.0922.6634.10
EBITDA margin+31.8%+33.4%+32.6%+23.9%+21.6%+16.2%+21.7%
Profit before tax47.2243.8632.707.8733.206.4321.02
Net profit34.2833.6326.468.5323.768.1815.00
Net profit margin+11.4%+13.5%+12.1%+4.5%+10.7%+5.8%+9.5%
EPS (₹)6.546.4235.3410.42344.2293.83220.48
Balance sheet
Total assets400304272254169143131
Net worth250214181157150126120
Total debt12888.8990.4896.8819.0216.4311.59
Cash & bank25.2415.5352.8154.622.834.353.82
Net working capital21.8920.8546.5046.120.523.47(7.31)
Cash flow
Cash from operations80.2362.8061.2344.9342.3323.5431.31
Cash from investing(51.25)(39.28)(35.04)(22.04)(43.69)(27.71)(19.90)
Cash from financing(28.15)(24.15)(25.83)(24.32)1.093.21(10.16)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue84.0978.5675.5876.2670.2864.1558.5765.95
Revenue growth (YoY)+19.7%+22.5%+29.0%+15.6%+16.3%---
Other income1.561.300.990.971.100.940.971.26
Total expenses55.1754.7552.3952.2946.4444.3240.4842.37
EBITDA28.9223.8123.1923.9723.8419.8318.0923.58
EBITDA margin+34.4%+30.3%+30.7%+31.4%+33.9%+30.9%+30.9%+35.8%
Depreciation10.6010.6910.119.659.158.668.628.58
Interest3.673.873.102.722.662.062.032.07
Profit before tax16.2110.5510.9712.5713.1310.058.4114.19
Tax3.633.842.823.203.282.032.063.43

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue87.6581.4177.6978.7372.5965.0959.5166.75
Revenue growth (YoY)+20.8%+25.1%+30.6%+18.0%+19.5%---
Other income1.090.790.620.850.910.820.601.31
EBITDA30.4524.3723.1624.1223.7519.1818.2523.19
EBITDA margin+34.7%+29.9%+29.8%+30.6%+32.7%+29.5%+30.7%+34.7%
Depreciation11.2811.2610.5610.149.488.738.838.75
Interest3.723.923.162.782.702.061.982.13
Profit before tax16.549.9810.0612.0512.489.218.0413.62
Tax3.683.822.823.223.302.042.063.48
Net profit12.866.167.248.839.187.175.9810.14
EPS (₹)2.501.211.441.731.801.421.181.94
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue310252219190223140158
Revenue growth+23.1%+15.3%+15.0%-14.8%+59.4%-11.1%-
Other income3.163.853.553.552.301.381.54
Total expenses214170149146175117123
Employee cost53.2642.8940.0739.8231.2623.0831.92
EBITDA96.1781.9370.1144.4348.0822.6234.10
EBITDA margin+31.0%+32.5%+32.1%+23.4%+21.5%+16.2%+21.7%
Depreciation41.4535.3032.6031.6715.0915.7112.59
Interest13.349.079.609.562.101.902.03
Profit before tax44.5441.4131.466.7533.196.3921.02
Tax13.1610.428.330.689.44(0.06)5.80
Net profit32.3732.0325.677.6824.768.1415.00
Net profit margin+10.4%+12.7%+11.7%+4.0%+11.1%+5.8%+9.5%
EPS (₹)6.186.1134.249.45344.2093.26220.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4210.428.538.538.538.538.53
Reserves & surplus234201171147141118111
Shareholders' funds (net worth)245211179156150126120
Minority interest(1.37)(1.01)(0.26)(0.47)0.000.000.00
Secured loans1.295.428.6414.0117.6214.837.57
Unsecured loans12983.4781.8482.871.401.604.02
Total debt13088.8990.4896.8819.0216.4311.59
Total liabilities397300270253169143131
Assets
Gross block453320274226211198194
Net block315223212195119119128
Capital work in progress36.9410.591.312.391.240.160.38
Investments0.001.000.000.000.005.415.38
Inventories8.148.056.686.166.234.455.45
Sundry debtors22.7613.818.874.687.576.006.00
Cash & bank balances26.3520.1155.0255.042.824.433.92
Loans & advances5.325.191.872.175.197.067.58
Total current assets62.5747.1672.4468.0521.8121.9422.95
Total current liabilities43.6027.9324.4321.8321.3718.4530.21
Net working capital18.9719.2348.0146.220.443.49(7.26)
Total assets397300270253169143131
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.252.522.163.192.933.922.56
Net cash from operating activities81.8363.3660.4844.1042.3423.5131.31
Net cash from investing activities(52.17)(39.58)(35.00)(20.79)(43.79)(27.71)(19.79)
Net cash from financing activities(28.69)(24.05)(25.13)(24.33)1.093.21(10.16)
Net change in cash0.97(0.27)0.36(1.03)(0.36)(0.99)1.36
Closing cash26.3520.1155.0255.042.824.433.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.1%+15.3%+15.0%-14.8%+59.4%-11.1%-
EBITDA growth+17.4%+16.9%+57.8%-7.6%+112.6%-33.7%-
PBT growth+7.6%+31.6%+366.1%-79.7%+419.4%-69.6%+9997.0%
Net income growth+1.1%+24.8%+234.2%-69.0%+204.2%-45.7%-
Revenue CAGR (3Y)+17.8%+4.1%+16.0%+6.5%---
EBITDA CAGR (3Y)+29.4%+19.4%+45.8%+9.2%---
Profitability & leverage
Net income margin+10.1%+12.3%+10.6%+3.2%+10.6%+4.6%+9.7%
Return on capital employed+16.6%+17.7%+15.7%+8.9%+22.6%+7.6%+17.5%
Return on net worth+13.8%+15.9%+13.9%+4.8%+17.4%+6.7%+12.9%
Debt / equity0.480.460.560.380.130.110.10
Long-term debt / equity0.410.380.460.300.080.070.06
Interest cover24.3819.4525.5974.926.3727.509.44
Efficiency & per share
Fixed asset turnover0.800.850.870.871.090.710.81
Inventory turnover38.3534.2334.0730.6941.8028.2828.90
Debtors turnover16.9822.2332.2831.0432.8923.3426.25
EPS (₹)6.186.1134.249.45344.2093.26220.48
Dividend per share (₹)0.050.000.000.000.000.000.00
Book value per share (₹)47.0140.56257.65223.622,149.921,805.721,712.46
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue84.0978.5675.5876.2670.2864.1558.5765.95
Revenue growth (YoY)+19.7%+22.5%+29.0%+15.6%+16.3%---
Other income1.561.300.990.971.100.940.971.26
Total expenses55.1754.7552.3952.2946.4444.3240.4842.37
EBITDA28.9223.8123.1923.9723.8419.8318.0923.58
EBITDA margin+34.4%+30.3%+30.7%+31.4%+33.9%+30.9%+30.9%+35.8%
Depreciation10.6010.6910.119.659.158.668.628.58
Interest3.673.873.102.722.662.062.032.07
Profit before tax16.2110.5510.9712.5713.1310.058.4114.19
Tax3.633.842.823.203.282.032.063.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue301249219190223140158
Revenue growth+20.7%+14.0%+15.0%-14.9%+59.4%-11.1%-
Other income4.354.383.653.582.301.381.54
Total expenses205166147145175117123
Employee cost51.6741.9139.6439.4634.1423.0531.92
EBITDA95.5483.2671.1945.4848.0922.6634.10
EBITDA margin+31.8%+33.4%+32.6%+23.9%+21.6%+16.2%+21.7%
Depreciation39.6034.7332.5731.6315.0915.7112.59
Interest13.079.059.579.562.101.902.03
Profit before tax47.2243.8632.707.8733.206.4321.02
Tax13.1510.428.320.689.44(0.06)5.80
Net profit34.2833.6326.468.5323.768.1815.00
Net profit margin+11.4%+13.5%+12.1%+4.5%+10.7%+5.8%+9.5%
EPS (₹)6.546.4235.3410.42344.2293.83220.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4210.428.538.538.538.538.53
Reserves & surplus239204172148141118111
Shareholders' funds (net worth)250214181157150126120
Secured loans1.225.428.5214.0119.0214.837.57
Unsecured loans12783.4781.9682.870.001.604.02
Total debt12888.8990.4896.8819.0216.4311.59
Total liabilities400304272254169143131
Assets
Gross block419312274226211198194
Net block284215211195119119128
Capital work in progress36.815.811.022.391.090.160.38
Investments6.312.711.160.500.165.525.48
Inventories8.128.026.656.046.234.455.45
Sundry debtors24.8615.069.154.697.576.006.00
Cash & bank balances25.2415.5352.8154.622.834.353.82
Loans & advances5.255.672.142.305.247.117.63
Total current assets63.4744.2870.7567.6521.8721.9122.90
Total current liabilities41.5823.4324.2521.5321.3518.4430.21
Net working capital21.8920.8546.5046.120.523.47(7.31)
Total assets400304272254169143131
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.482.111.753.192.863.822.56
Net cash from operating activities80.2362.8061.2344.9342.3323.5431.31
Net cash from investing activities(51.25)(39.28)(35.04)(22.04)(43.69)(27.71)(19.90)
Net cash from financing activities(28.15)(24.15)(25.83)(24.32)1.093.21(10.16)
Net change in cash0.83(0.63)0.36(1.44)(0.28)(0.96)1.26
Closing cash25.2415.5352.8154.622.834.353.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+20.7%+14.0%+15.0%-14.9%+59.4%-11.1%-
EBITDA growth+14.8%+17.0%+56.5%-5.4%+112.2%-33.6%-
PBT growth+7.7%+34.1%+315.5%-76.3%+416.3%-69.4%-4.0%
Net income growth+1.9%+27.1%+210.2%-64.1%+190.5%-45.5%-
Revenue CAGR (3Y)+16.5%+3.7%+16.0%+6.5%+13.9%+2.0%-
EBITDA CAGR (3Y)+28.1%+20.1%+46.5%+10.1%+10.9%-4.0%-
Profitability & leverage
Net income margin+11.3%+13.4%+11.2%+3.8%+10.7%+4.6%+9.7%
Return on capital employed+17.1%+18.4%+16.1%+9.4%+22.6%+7.6%+17.2%
Return on net worth+14.7%+17.0%+14.6%+5.6%+17.4%+6.7%+13.8%
Debt / equity0.470.450.560.380.130.110.14
Long-term debt / equity0.400.380.460.300.080.070.07
Interest cover23.3618.6524.7869.036.3627.349.44
Efficiency & per share
Fixed asset turnover0.820.850.870.871.090.710.84
Inventory turnover37.2633.9634.4430.9741.8028.2827.80
Debtors turnover15.0620.5831.5830.9932.8923.3425.30
EPS (₹)6.546.4235.3410.42344.2293.83220.48
Dividend per share (₹)0.050.000.000.000.000.000.00
Book value per share (₹)47.9641.15259.76224.632,150.511,806.301,712.46

Timeline of Suraksha Diagnostics

5 dated milestones of Suraksha Diagnostics across 19 years, from founding to its latest funding, stage changes and deals.

  1. Founded Suraksha Diagnostics is founded.
  2. Funding First funding round of $9.0M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Series B, of $40.0M.
  5. IPO Lists on the stock exchange (IPO).

Competitors of Suraksha Diagnostics

Suraksha Diagnostics has 3 listed competitors in our database, 1 of them funded. They include Thyrocare, Aarthi Scans and Vijaya Diagnostic Centre.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Thyrocare
thyrocare.com1996Mumbai, India$63.59M1,889
Diagnostic testing centers for pathology and health screenings are operated.
Aarthi Scans
aarthiscan.com2000Chennai, India1,931
Chain of diagnostic centers
Vijaya Diagnostic Centre
vijayadiagnostic.com1981Hyderabad, India
Diagnostic services are offered via a chain of centers.
Premium access

Detailed competitors of Suraksha Diagnostics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Suraksha Diagnostics

The website of Suraksha Diagnostics (surakshanet.com) receives about 101.3K visits a month.

  • Monthly visits
    101.3K

    ▼ 14.2% vs previous month

Similar websites

Websites whose visitors overlap most with Suraksha Diagnostics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Pulse Diagnostics
pulsediagnostics.com
100%
8.4K#2,936,650View details
Quadra Medical Services
quadradiagnostics.com
91%
18.3K#1,318,871View details
f1check.rediff.com
f1check.rediff.com
90%
–
AmbujaNeotia
ambujaneotia.com
90%
12.3K#1,881,136View details
lifesonmanipal.com
lifesonmanipal.com
60%
#312,243–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 12 similar websites and full traffic analytics for Suraksha Diagnostics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 12 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Diagnostics Laboratories

3 companies that operate in the same segment as Suraksha Diagnostics (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Thyrocare
Diagnostic testing centers for pathology and health screenings are operated.
1996Mumbai, Maharashtra, IndiaUSD 63.59 MUSD 88.36 M1,950
Dr Lal PathLabs
Chain of pathology and radiology labs
1949Gurugram, Haryana, IndiaUSD 13.9 MUSD 294.49 M5,310
Redcliffe Labs
Home-based diagnostic tests are booked via an online platform.
2018Noida, Uttar Pradesh, IndiaUSD 116.42 MUSD 41.86 M2,308
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Suraksha Diagnostics

Suraksha Diagnostic consolidated net profit rises 38.40% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Suraksha Diagnostic Says K S Ravindra Resigns As Group CFO
Reuters • 7 months ago
Suraksha Diagnostic consolidated net profit rises 18.39% in the June 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Suraksha Diagnostic consolidated net profit rises 13.34% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Suraksha Diagnostic standalone net profit rises 17.11% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Stock Market Live Updates 11 March 2025: Sensex, Nifty trim losses, IndusInd Bank plunges 25%
Thehindubusinessline • 1 year ago
Share Market Highlights 11 March 2025: Sensex, Nifty settle flat in lacklustre trade; IndusInd Bank tumbles
Thehindubusinessline • 1 year ago
Stock Market Live Updates 10 March, 2025: Sensex, Nifty open on cautiously positive note; Power Grid leads, while IndusInd Bank slumps
Thehindubusinessline • 1 year ago
Share Market Highlights March 10, 2025: Sensex drops 217 points, Nifty settles at 22,460; Power Grid, HUL top gainers
Thehindubusinessline • 1 year ago
Suraksha Diagnostic Approves Formation Of Spv With Suraksha Diagnostic & Eye Centre
Reuters • 1 year ago
Premium access

Complete news archive for Suraksha Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suraksha Diagnostics

Suraksha Diagnostics was founded in 2005 and raised its 1st funding round 8 years after it was founded.

Suraksha Diagnostics is headquartered in Kolkata, India. It is registered at Kolkata, West Bengal, India.

Raman Kejriwal is the CEO of Suraksha Diagnostics, as recorded in our data.

Suraksha Diagnostics is a funded company, having raised a total of $49M across 2 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on Feb 2013.

Suraksha Diagnostics has 1,300 employees.

The primary company behind Suraksha Diagnostics, Suraksha Diagnostic Limited, reported revenue of ₹11.40 Cr for FY 2025, up 19% year on year.

Suraksha Diagnostics was founded in 2005 in Kolkata, India, as a provider of diagnostic services in the healthcare sector. A wide range of tests is offered, including radiology, histopathology, molecular biology, cytogenetics, cardiology, gastroenterology, and neurology. Operations are supported by online booking for tests and electronic access to medical reports via the website, serving patients across the region.

Suraksha Diagnostics's top competitors include Thyrocare, Vijaya Diagnostic Centre and Aarthi Scans.

Suraksha Diagnostics offers MRI Scan, X Ray, Pathology Testing, ECG Test, and Blood Tests.

Yes, Suraksha Diagnostics is publicly traded on NSE under the ticker symbol SURAKSHA.

Suraksha Diagnostics has 2 investors. Key investors include Orbimed, and Lighthouse Funds.

The valuation of Suraksha Diagnostics is $35.76M as of Feb 2013.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available